Gallium‐68 DOTATATE PET in the Evaluation of Intracranial Meningiomas

Meningiomas are the most common primary intracranial tumors, typically treated with surgery and adjuvant radiation in cases of subtotal resection and/or higher histopathologic grade. Contrast‐enhanced magnetic resonance imaging (MRI) is the gold standard for postoperative assessment and adjuvant treatment planning. However, MRI can have limited accuracy particularly in the presence of posttreatment change. [68Ga]‐DOTATATE is a Positron Emission Tomography (PET) radiotracer targeting somatostatin receptor 2A (SSTR2A). SSTR2A is a reliable biomarker of meningiomas. We report a consecutive case series of 20 patients evaluated with [68Ga]‐DOTATATE PET/MRI, propose a novel approach to quantitative analysis, and discuss clinical implications.

[1]  Jason M. Johnson,et al.  The Use of 68Ga-DOTATATE PET/CT in the Non-invasive Diagnosis of Optic Nerve Sheath Meningioma: A Case Report , 2018, Front. Oncol..

[2]  R. Flavell,et al.  Detection of Metastatic Meningioma to the Liver Using 68Ga-DOTA-Octreotate PET/CT. , 2018, Clinical nuclear medicine.

[3]  U. Haberkorn,et al.  Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy , 2018, Radiation oncology.

[4]  M. Weller,et al.  PET imaging in patients with meningioma—report of the RANO/PET Group , 2017, Neuro-oncology.

[5]  M. Reiser,et al.  Improved Detection of Transosseous Meningiomas Using 68Ga-DOTATATE PET/CT Compared with Contrast-Enhanced MRI , 2017, The Journal of Nuclear Medicine.

[6]  M. Weller,et al.  Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. , 2016, Neuro-oncology.

[7]  C. Leães,et al.  Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. , 2015, International journal of clinical and experimental pathology.

[8]  A. Gown,et al.  Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen , 2015, Acta Neuropathologica.

[9]  U. Schüller,et al.  Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue , 2015, The Journal of Nuclear Medicine.

[10]  M. Roethke,et al.  Comparison of ⁶⁸Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. , 2015, Neuro-oncology.

[11]  Bernd J Pichler,et al.  Combined PET/MR: A Technology Becomes Mature , 2015, The Journal of Nuclear Medicine.

[12]  P. Wen,et al.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. , 2014, Neuro-oncology.

[13]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[14]  U. Haberkorn,et al.  Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  T. Beyer,et al.  Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. , 2011, International journal of radiation oncology, biology, physics.

[16]  A. Jouvet,et al.  WHO grade II and III meningiomas: a study of prognostic factors , 2009, Journal of Neuro-Oncology.

[17]  Jeong Won Lee,et al.  18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Ciprian Catana,et al.  Simultaneous PET-MRI: a new approach for functional and morphological imaging , 2008, Nature Medicine.

[19]  Habib Zaidi,et al.  PET versus SPECT: strengths, limitations and challenges , 2008, Nuclear medicine communications.

[20]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[21]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[22]  A. Jena,et al.  Somatostatin receptor-positive granulomatous inflammation mimicking as meningioma on simultaneous PET/MRI. , 2015, Clinical nuclear medicine.

[23]  P. Wen,et al.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review , 2014 .